October 23, 2019
Viz.ai Raises Funds to Support Product Development and Commercialization
October 23, 2019—Viz.ai, a developer of synchronized health care software using artificial intelligence, announced a $50 million Series B funding to expand the benefits of synchronized care with the company’s products to more disease states and geographies.
The company’s Viz LVO computer-aided triage and notification software leverages advanced deep learning to communicate time-sensitive information about patients' suspected large-vessel occlusions directly to a stroke team specialist who can intervene and treat.
In February 2018, the FDA granted a de novo clearance for Viz LVO. The company received FDA 510(k) clearance for Viz CTP, a tool for automated cerebral perfusion image analysis. Viz.ai’s acute ischemic stroke software is available in more than 300 hospitals in the United States.
The funding round was led by Greenoaks with participation from Threshold Ventures, CRV along with existing investors GV and Kleiner Perkins.